Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Director | August 01, 2022 | August 03, 2022 |
| Tintri, Inc.TNTR · Entity 165007 | Director | June 29, 2017 | June 29, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,100 |
Reported balance
After 2022-08-01 transaction · row 1
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 1,600 · Balance 5,100 F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.
Tintri, Inc.
Report date June 29, 2017 · Filed June 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,166 |
Reported balance
Holding disclosure · report date 2017-06-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,166 F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 3/8 of the RSU's vest on the closing of the Issuer's initial public offering and an additional 1/8 of the RSU's shall vest on the 15th day of the following months of September, December, March and June. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.68 · Expires 2025-12-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-06-29 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 1/48 of the shares subject to the option vested on January 8, 2016 and an additional 1/48 of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit (RSU). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 3/8 of the RSU's vest on the closing of the Issuer's initial public offering and an additional 1/8 of the RSU's shall vest on the 15th day of the following months of September, December, March and June.
F2: 1/48 of the shares subject to the option vested on January 8, 2016 and an additional 1/48 of the shares vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2020 Filed May 27, 2020 23:48 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 8,677 | $15.36 | $133,288.26 |
DisclosureSEC source: 0001209191-20-032439 · doc4.xml · nonDerivative · entry 3 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,296 F1 · price: The shares were sold in multiple transactions at prices ranging from $15.29 to $15.48, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:48 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Exercise / conversionCommon Stock | 2,631 | $0.38 | $999.78 |
DisclosureSEC source: 0001209191-20-032439 · doc4.xml · nonDerivative · entry 2 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:48 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Exercise / conversionCommon Stock | 2,500 | $3.93 | $9,812.50 |
DisclosureSEC source: 0001209191-20-032439 · doc4.xml · nonDerivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001209191-19-033853 · doc4.xml · derivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 30, 2019, and 1/16th of such shares vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001209191-18-031800 · doc4.xml · derivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-05-18 F1 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 18, 2018, and 1/16th of such shares vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date. Read SEC document |
| May 16, 2017 Filed Jun 13, 2017 00:23 UTC Amendment | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039311 · doc4a.xml · nonDerivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,842 F1 · shares: Represents an award of 2,000 restricted stock units ("RSUs") granted to Mr. Bolger in connection with his reelection as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after May 16, 2017, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date. F2 · shares: This amendment is being filed because the name of the reporting person was incorrect in the Form 4 as originally filed. This line item is being re-reported in this amendment in order to gain access to the filing system for purposes of filing this amendment. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 20:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147290 · doc4.xml · nonDerivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,842 F1 · shares: Represents an award of 4,842 restricted stock units ("RSUs") granted to Mr. Bolger in connection with his appointment as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after September 28, 2016, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Mr. Bolger's continued service for the Issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantIssuer Stock Option (Right to Buy) · Derivative | 2,631 | Not disclosed Strike: $12.31 | Not disclosed |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 8 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,631 Underlying: Issuer Common Stock · 2,631 shares Expires 2026-06-21 F6 · price: The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units. F3 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantIssuer Stock Option (Right to Buy) · Derivative | 2,631 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 7 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,631 Underlying: Issuer Common Stock · 2,631 shares Expires 2026-04-12 F6 · price: The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units. F2 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantIssuer Stock Option (Right to Buy) · Derivative | 2,631 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 6 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,631 Underlying: Issuer Common Stock · 2,631 shares Expires 2026-02-22 F6 · price: The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units. F4 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after February 23, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Disposition to issuerPredecessor Unit Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $1.62 | Not disclosed |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 5 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares Expires 2026-06-21 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. F5 · price: The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock. F3 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Disposition to issuerPredecessor Unit Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 4 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares Expires 2026-04-12 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. F5 · price: The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock. F2 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Disposition to issuerPredecessor Unit Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 3 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares Expires 2026-02-22 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. F5 · price: The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock. F4 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after February 23, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
| June 22, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantPredecessor Unit Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 2 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares Expires 2026-06-21 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. F3 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
| April 13, 2016 Filed Oct 4, 2016 22:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantPredecessor Unit Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares Expires 2026-04-12 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. F2 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.